论文部分内容阅读
盐酸伊立替康是拓扑异构酶I的特异性抑制剂,有广谱、强效的抗肿瘤活性,盐酸伊立替康及其代谢物对表达多药耐药的肿瘤仍然有效,可有效治疗小细胞及非小细胞肺癌、子宫颈癌、卵巢癌、胃癌、转移性结直肠癌、恶性淋巴瘤等多种肿瘤[1]。迟发性腹泻与中性粒细胞减少症是盐酸伊立替康的主要不良反应,是可预测、可逆转、可控制、无蓄积的,
Irinotecan hydrochloride is a specific inhibitor of topoisomerase I with broad spectrum and potent anti-tumor activity. Irinotecan and its metabolites are still effective in expressing multidrug-resistant tumors and can effectively treat small Cell and non-small cell lung cancer, cervical cancer, ovarian cancer, gastric cancer, metastatic colorectal cancer, malignant lymphoma and other tumors [1]. Delayed diarrhea and neutropenia are the major adverse events of irinotecan hydrochloride and are predictive, reversible, controllable, and non-accumulative,